Tuesday, November 17, 2026

Why I Keep Expecting Science to Find More Design

Over the years, I've often been skeptical of many modern evolutionary explanations. People usually assume it's because I'm religious.

That's only part of the story.

Originally, my opposition to evolution was purely religious. The Bible said God created the world and the life within it, so that settled the matter as far as I was concerned. I purchased a book on Scientific Creationism, felt pretty confident in my position, and in the early 1990s began frequenting atheist and evolutionist chat rooms. Armed with what I thought was solid knowledge, I expressed that confidence freely, only to have my hat handed to me by people who knew far more science than I did and came equipped with papers and research that seemed to demonstrate the undeniability of evolutionary theory.

As I read those papers, hoping to find flaws, I was struck by the sheer volume of information I was up against. At first, the experience was discouraging. I openly wondered whether my faith was even valid. Rather than walk away, however, I decided to dig deeper. The more interested I became in science, the more I discovered that the research was rarely as conclusive as it was sometimes portrayed in popular discussions. Good scientists don't permanently close doors. They follow evidence and remain willing to revise conclusions when new evidence appears.

Then two important things happened. In 1996, I was offered an apprenticeship as a manufacturing plant electrician. About a decade later, I encountered Thomas Aquinas and his arguments for God's existence, including what is known as the Fifth Way.

As an electrician, I learned the art of troubleshooting industrial machinery. Day after day, I diagnosed failures by tracing wiring diagrams, learning relay logic, PLC logic, and CNC logic, and trying to understand how complex electrical, pneumatic, hydraulic, mechanical and electronic systems worked individually and how they fit together. That experience fundamentally changed the way I look at the world.

One thing you learn very quickly as a maintenance electrician is that complex systems are almost never as simple as they appear. The wire that seems unnecessary usually isn't. The logic you don’t fully understand often performs a critical function. What looks straightforward on the surface frequently turns out to be governed by layers of hidden logic, feedback loops, contingencies, and safeguards. The deeper you investigate, the more organization you discover.

Because of that background, something about many biological explanations always struck me as odd. Researchers would identify some component of life and conclude that it was probably a leftover, a historical relic, a meaningless byproduct, or an accident of history. To me, that never sounded quite right. My instinct was exactly the opposite. If living systems are designed, then deeper investigation should reveal deeper purpose.

That mindset led me to make a number of predictions on various discussion sites around 2007. I predicted that so-called "junk DNA" would eventually be found to perform important functions. I predicted that genetic systems would prove far more sophisticated than scientists then realized. I expected hidden regulatory networks to be discovered, and I anticipated that biological information would turn out to be layered, overlapping, and densely packed.

I wasn't making those predictions because I had extensive biological expertise. I was making them because I spent my days working with complex engineered systems. Looking back, many of those expectations have aged surprisingly well. The more researchers probe the cell, the more layers of information they seem to find. The more carefully genomes are studied, the more functionality appears in regions once considered insignificant. The more we learn, the more life resembles an integrated information-processing system.

None of that proves God. No single scientific discovery ever will. But it does raise an interesting question: Why does nature continue to reveal deeper layers of organization?

This is where Aquinas' Fifth Way became important to me. Until I discovered the Fifth Way, I had been using the standard Intelligent Design 'Watchmaker' argument: that a complex system requires an intelligent designer. But the Fifth Way is not an argument from complexity. It isn't the claim that because things are complicated, they must have been assembled by a divine mechanic. Aquinas' logic does not depend on the system being complicated. His logic is about why the system is ordered at all.

Aquinas compared nature to an arrow shot at a target. The arrow doesn't have the capacity to guide itself toward the target; it must be directed by something with the capacity to aim it. He argued that the regular, goal-directed behavior we observe throughout nature points beyond the constituent things themselves. This applies to all levels of nature, not just the complex ones.

The Fifth Way is, at its core, an argument about the outcomes of organization. Why do unintelligent things consistently behave in ways that produce organized outcomes? Hydrogen and oxygen reliably combine to form water. Water reliably flows, evaporates, condenses, and flows again. Across nature, matter behaves according to patterns that generate stable systems, often revealing layers of sophisticated organization. Does nature possess this organizing power entirely within itself? Or does the order we observe point to something with the capacity, and the vision, to organize it?

As an electrician, when I see components consistently interacting to produce predictable outcomes, I infer that the system possesses an underlying logic or reason for that.

Modern science generally operates under the methodological assumption that natural processes are sufficient to explain these natural phenomena. Given enough time, stars form, planets form, life emerges, and eventually conscious beings appear to wonder about their own existence. Increasingly, however, I've found myself wondering whether that assumption sometimes plays a role similar to the geocentric model in earlier centuries.

When scientists working within the geocentric system encountered conflicting observations, additional layers of explanation were introduced to preserve the underlying premise. Today, I often see something similar happening within the broader evolutionary narrative. Ancient galaxies appear earlier than expected. Complex life appears earlier than expected. Genetic systems prove more sophisticated than expected. New layers of regulation and function continue to emerge. Each surprise is ultimately incorporated into the existing framework.

Maybe that's exactly what science should do. Or maybe, one day, we'll discover that the underlying premise itself requires reconsideration.

I don't claim to have all the answers, and I certainly don't view science as the enemy. In fact, I love science. To me, science is simply the process of discovering how creation works. What fascinates me is that the more science advances, the less accidental the universe appears.

The more I learn, the more it reminds me of something familiar: a machine. Not a machine in the cold, mechanical sense, but a machine filled with layers of information, coordination, purpose, and logic that reveal themselves only through careful investigation.

After decades spent tracing logic and diagnosing systems, I've developed certain expectations about what design looks like. When I examine nature, I find those expectations confirmed far more often than challenged.

That's why I keep expecting science to find more design.

And so far, it keeps giving me more reasons to do exactly that.


Thursday, November 5, 2026

The Case of the Missing Agent

 



From traits to trajectories: development, agency and a phenotypic gap in demography

The author correctly recognizes that agency and decision making are what's missing in evolutionary models, but misses the mark by ascribing these qualities to the building blocks rather than to the Builder.

Sunday, November 1, 2026

A Thought Experiment

 


Imagine a race of immaterial beings who have the ability to see the physical world all the way down to the atomic level.

Imagine that they can also see through the outer layers and zoom into any desired area inside a physical object to observe the molecular workings and interactions there.

Imagine next that these beings come to Earth to look for technology of the highest order.

Would they be most impressed by human inventions, or by the molecular machinery of life? 

Discuss.

Sunday, May 31, 2026

Ivermectin vs. Cancer



This page grew out of my Ivermectin vs. COVID-19 page.  While collecting links on that subject I ran across numerous papers on ivermectin and cancer and started collecting them here.

I am not a medical doctor, so I will let the studies speak for themselves.

On a cautionary note, one study has found that a significant percentage of people (16% in the small study) have a genetic mutation that inhibits the metabolism of ivermectin.  In those patients, side effects such as “delirium-like behavior, agitation, aggressive attitude, and altered state of consciousness” occurred.  Although the mutation is not mentioned in this paper, it may document a possible incidence of this.

Papers

Cancers in general.

Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review

Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort

Systemic Repurposing of Antiparasitic Agents in Oncology: From Molecular Pleiotropy of Mebendazole and Ivermectin to Clinical Validation

Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential

Antiproliferative and trypanocidal activity of ivermectin bioconjugates

Ivermectin Mitigates Lung Toxicity Induced by γ-radiation in Rats via TLR4/ NF-κB /MAPK Pathways

Anthelmintic Drugs as Emerging Immune Modulators in Cancer

Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures

Repurposing Vermicide Ivermectin as Medicine in Oncology to Treat Cancer- The Silent but Accessible Role Player in Sustainable Innovation

Inhaled Ivermectin-Loaded Lipid Polymer Hybrid Nanoparticles: Development and Characterization

Ivermectin and its synthetic derivatives – A new class of anticancer agents

Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy

Ivermectin A Potential Repurposed Anti-Cancer Therapeutic

Ivermectin: The future of Cancer Treatment

Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador

Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway

Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-loaded Squalene Emulsion

Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy

Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin

Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

Inhibition of TMEM16A Ca2+-activated Cl− channels by avermectins is essential for their anticancer effects

Ivermectin kills cancer cells via catastrophic changes in the endoplasmic reticulum structure

Old wine in new bottles: Drug repurposing in oncology

Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells

Fibrosarcoma

Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review

Lymphoma

Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts

Lung cancer

Inhalable ivermectin-loaded lipid-polymer hybrid nanoparticles as a promising anticancer platform for non-small cell lung cancer

Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts

Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects against urethane-induced non-small cell lung cancer in BALB/c mice

Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells

Multiple myeloma

Assessing the potential of ivermectin against t(4;14) multiple myeloma.

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma

Pancreatic cancer

Triple Combination of Recombinant Methioninase and the Anti‐parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts

Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells

Ivermectin suppresses pancreatic cancer via mitochondria dysfunction

Prostate cancer

Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway

Integrated analysis reveals FOXA1 and Ku70/Ku80 as direct targets of ivermectin in prostate cancer

Breast cancer

Ameliorative Effects of Ivermectin (Iverzine®) Against DMBA-Induced Mammary Carcinogenesis in Female Wistar Rats: Biochemical, Hormonal, Oxidative Stress, Molecular and Histopathological Investigations

Ivermectin B1a sensitizes TNBC cells to cyclophosphamide therapy in vitro by targeting PITRM1/SLC7A11-mediated ferroptotic pathway

Combination of ivermectin and metformin promotes autophagy in MCF‑7 cells by inhibiting phosphorylation of the PI3K/AKT/mTOR pathway

Hybrid platelet membrane stearic acid liposomes for targeted delivery of ivermectin in triple-negative breast cancer

Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells

Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management

Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells

A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition

Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin

Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model

Genotoxicity and Anti-Cancer Activity of Tamoxifen and Ivermectin Loaded Chitosan Nanoparticles Against MCF-7 Cell Line

STRUCTURAL AND MOLECULAR CHARACTERIZATION OF LOPINAVIR AND IVERMECTIN AS BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) INHIBITORS

Ivermectin Induces Oxidative Stress and DNA Damage in Breast Cancer Cells


Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death

Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling

The PAK1-Stat3 Signaling Pathway Activates IL-6Gene Transcription and Human Breast Cancer Stem Cell Formation

Ivermectin as an inhibitor of cancer stem‑like cells

Bone cancer 

Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma 

Ovarian cancer 

IVERMECTIN LOADED SOLID LIPID NANOPARTICLES FOR OVARIAN CANCER TREATMENT: DEVELOPMENT, CHARACTERIZATION AND ENHANCED CYTOTOXIC ACTIVITY 

Ivermectin decreases the expression of ALDH1 in ovarian cancer cell lines in combination with chemotherapy 

Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches 

Ivermectin: an ally to reverse P-glycoprotein-associated multidrug resistance in ovarian cancer 

Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells 

The Use of Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) to Study Ivermectin-Mediated Molecular Pathway Changes in Human Ovarian Cancer Cells 

The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer

Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine

Ivermectin inactivates the kinase PAK1 and blocks the PAK1- dependent growth of human ovarian cancer and NF2 tumor cell lines

SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells

Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes

Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.

Cervical cancer

Insights into the Therapeutic Potential of Combining Ivermectin and Ascorbic Acid Against HPV-Induced Cervical Cancer: A Mini Review 

Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media 

Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway 

Oral squamous cell carcinoma (OSCC)

Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation

Esophageal squamous cell carcinoma (ESCC)

Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway

Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma

Oral Cancer

When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer

Renal cancer

“Ivermectin synergizes with interferon-gamma to overcome resistance in renal cancer”

Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage

Glioma

Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas

Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells

Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress

Nasopharyngeal carcinoma 

Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

Melanoma

Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors

Suppressing ROS‐TFE3‐dependent autophagy enhances ivermectin‐induced apoptosis in human melanoma cells

Gastric cancer

Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer

Liver cancer

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice

Leukemia

Ivermectin and dexamethasone combination induces apoptosis in SUP-B15 cell line

Alendronate/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia

Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy

Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress

The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

Colorectal cancer

Colon cancer

Bladder cancer

Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.

Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells

Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach

Clinical Trials

Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer. ClinicalTrials.gov ID: NCT05318469

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) ClinicalTrials.gov ID: NCT02366884

List of Ivermectin/Cancer trials at clinicaltrials.gov

Articles

Repurposing Ivermectin and Mebendazole for Cancer: What the New Real-World Data Tells Us, and What It Cannot

Ivermectin and Cancer: Why This Nobel Prize Drug Is Forcing a Rethink of Oncology

Ivermectin Reverses Breast Cancer!

Ivermectin for Parasites, but as a PAK1 Inhibitor for Autism, Cancer and Leukemia?